This year WHO released eagerly anticipated comprehensive antiretroviral treatment (ART) guidelines addressing how to optimize ART for both treatment and prevention. The guidance recommends raising the CD4 threshold for treatment initiation to 500 CD4 cells or below—with priority given to people who are symptomatic or have CD4 cell counts at or below 350. As the graphic on page 37 illustrates, this shift in guidelines will increase the gap between the number of people eligible for ART worldwide and those currently receiving it. According to analyses included in the new guidelines, implementation of the new criteria for ART initiation stands to reduce annual incidence and mortality more than 33 percent by 2026.

There has been considerable discussion about the feasibility of implementing these guidelines and the need to address the gaps in the “treatment cascade”—the steps that move an HIV-positive individual from an initial HIV-positive test result to care to ART initiation to sustained, effective ART treatment.

The reality that sometimes gets lost in this discussion is that ART doesn’t preserve health and reduce transmission risk—virologic suppression does. Virologic suppression—having a viral load that is at or close to undetectable—is key to reducing the risk of transmission. (Right now, virologic suppression can only be achieved through effective ART and management of HIV-related infections—though investigations into therapeutic vaccines and a cure could lead to other options in the long run.)

To make progress toward virologic suppression, it has to be measured. One key step to take in the coming year is to expand access to viral load testing. The new WHO guidelines recommend viral load monitoring as the “preferred approach compared with immunological and clinical monitoring.” This is a shift away from previous guidelines that recommended monitoring CD4 count and clinical outcomes to gauge the response to ART. The Guidelines recommend routine testing defined as every six to 12 months—or “at least every 12 months”.

---

Implementing routine viral load testing would be a major shift for many of the countries with high HIV burdens. There is limited access to viral load testing in sub-Saharan Africa. Having a viral load test should never be a prerequisite for accessing care. However, if the world is serious about using treatment as prevention as part of comprehensive combination prevention, then expanding access to this monitoring test should be a priority.

There are many benefits to making viral load testing more routine: Knowledge that viral load is undetectable can be a profound motivation for people to adhere to treatment regimens, and detectable viral load can be an early warning sign that adherence counseling needs to be intensified. In the best-case scenario, this intensified counseling helps a person do better on his or her current ART combination, avoiding the need to change to a second- or third-line regimen.

Virologic suppression is achieved when people take their drugs correctly and consistently. For many people, this level of adherence requires support from ART programs, peer educators, family and friends. It also requires that drugs be in stock at clinics that are accessible to people wherever they live. Scale up of viral load testing needs to be accompanied by innovative ART service delivery. Approaches to adherence support should be evaluated through analysis of retention records at clinics as well as viral load samples (a rough picture of adherence levels at a clinic can be obtained by measuring viral load in pooled samples from several patients.)